Voyager Therapeutics, Inc. (NASDAQ:VYGR) Shares Sold by Renaissance Technologies LLC

Renaissance Technologies LLC cut its stake in Voyager Therapeutics, Inc. (NASDAQ:VYGR - Free Report) by 49.8% in the fourth quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund owned 139,900 shares of the company's stock after selling 138,767 shares during the quarter. Renaissance Technologies LLC owned about 0.26% of Voyager Therapeutics worth $793,000 as of its most recent SEC filing.

Other institutional investors have also modified their holdings of the company. Geode Capital Management LLC raised its stake in Voyager Therapeutics by 0.6% during the third quarter. Geode Capital Management LLC now owns 1,079,509 shares of the company's stock worth $6,316,000 after purchasing an additional 6,740 shares during the period. Barclays PLC lifted its holdings in Voyager Therapeutics by 55.8% in the third quarter. Barclays PLC now owns 104,462 shares of the company's stock valued at $612,000 after acquiring an additional 37,398 shares during the last quarter. Allspring Global Investments Holdings LLC grew its position in Voyager Therapeutics by 23.9% in the fourth quarter. Allspring Global Investments Holdings LLC now owns 39,313 shares of the company's stock worth $223,000 after acquiring an additional 7,573 shares during the period. Rhumbline Advisers increased its stake in Voyager Therapeutics by 3.4% during the fourth quarter. Rhumbline Advisers now owns 71,497 shares of the company's stock worth $405,000 after acquiring an additional 2,354 shares during the last quarter. Finally, American Century Companies Inc. lifted its stake in shares of Voyager Therapeutics by 8.1% in the 4th quarter. American Century Companies Inc. now owns 122,726 shares of the company's stock valued at $696,000 after purchasing an additional 9,190 shares during the last quarter. Hedge funds and other institutional investors own 48.03% of the company's stock.

Voyager Therapeutics Trading Up 0.9 %

VYGR traded up $0.03 on Wednesday, hitting $3.28. 324,915 shares of the company were exchanged, compared to its average volume of 444,551. The company has a market cap of $181.43 million, a price-to-earnings ratio of 4.62 and a beta of 0.95. The firm has a 50-day moving average price of $3.54 and a two-hundred day moving average price of $4.98. Voyager Therapeutics, Inc. has a twelve month low of $2.75 and a twelve month high of $9.55.

Voyager Therapeutics (NASDAQ:VYGR - Get Free Report) last announced its quarterly earnings data on Monday, May 12th. The company reported ($0.53) EPS for the quarter, missing analysts' consensus estimates of ($0.35) by ($0.18). The firm had revenue of $6.47 million during the quarter, compared to analysts' expectations of $13.55 million. Voyager Therapeutics had a net margin of 15.80% and a return on equity of 8.33%. Equities analysts expect that Voyager Therapeutics, Inc. will post -0.91 EPS for the current year.

Insider Transactions at Voyager Therapeutics

In related news, CEO Alfred Sandrock sold 10,885 shares of the stock in a transaction on Wednesday, April 2nd. The shares were sold at an average price of $3.43, for a total value of $37,335.55. Following the transaction, the chief executive officer now directly owns 430,931 shares of the company's stock, valued at $1,478,093.33. This trade represents a 2.46 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Insiders own 4.53% of the company's stock.

Wall Street Analyst Weigh In

A number of analysts recently issued reports on VYGR shares. HC Wainwright reissued a "buy" rating and set a $30.00 price objective on shares of Voyager Therapeutics in a research report on Tuesday, April 8th. Canaccord Genuity Group reduced their price target on shares of Voyager Therapeutics from $14.00 to $12.00 and set a "buy" rating on the stock in a research note on Thursday, March 13th. Wedbush reiterated an "outperform" rating on shares of Voyager Therapeutics in a report on Wednesday, March 12th. Cantor Fitzgerald restated an "overweight" rating on shares of Voyager Therapeutics in a research note on Wednesday, March 12th. Finally, Wells Fargo & Company set a $10.00 price objective on Voyager Therapeutics and gave the company an "overweight" rating in a research note on Wednesday, March 12th. One equities research analyst has rated the stock with a hold rating, eight have given a buy rating and one has issued a strong buy rating to the company's stock. Based on data from MarketBeat, Voyager Therapeutics presently has a consensus rating of "Buy" and a consensus target price of $13.97.

Voyager Therapeutics Company Profile

Voyager Therapeutics, Inc, a biotechnology company, focuses on the treatment of gene therapy and neurology diseases. The company's lead clinical candidate is VY-TAU01, an anti-tau antibody program for the treatment of alzheimer's disease. Its product pipeline includes superoxide dismutase 1 silencing gene therapy, which is in preclinical trial for the treatment of amyotrophic lateral sclerosis; tau silencing gene therapy, which is in preclinical trial for the treatment of alzheimer's disease; and vectorized anti-amyloid antibody, a gene therapy targeting anti-amyloid for the treatment of alzheimer's disease and is in preclinical trial.